Background. NRG Oncology/NSABP trial B-40 tested the impact of adding bevacizumab (bev) to neoadjuvant chemotherapy for operable breast cancer. Secondary endpoints included rates of surgical complications after surgery in patients who did or did not receive bev. Methods. A total of 1206 women with HER2-negative operable breast cancer were randomly assigned to receive one of three different docetaxel-plus-anthracycline-based regimens, without or with bev (15 mg/kg every 3 weeks) for the first 6 of 8 cycles and for 10 doses postoperatively. Surgical complications were assessed from date of surgery through 24 months following study entry. Results. Early surgical complications were significantly more frequent in the bev group (25.4 vs. 18.9%; trend test p = 0.008), but most were grade 1-2. Early noninfectious wound dehiscences were infrequent and not significantly different (5.4 vs. 3.1%; trend test p = 0.15). Long-term noninfectious wound complications were significantly higher for patients receiving bev (11.8 vs. 5.1%; trend test p = 0.0007), but the incidence of grade C3 wound dehiscence was low in both groups (\1%). Among 193 patients undergoing expander or implant reconstructions, 19 (19.6%) of 97 in the bev-receiving group versus 10 (10.4%) of 96 in the non-bev group had grade C3 complications (Pearson, p = 0.11). Conclusions. Overall, adding bev increased surgical complications, but most serious complications were not Electronic supplementary material The online version of this article
regimens, without or with bev (15 mg/kg every 3 weeks) for the first 6 of 8 cycles and for 10 doses postoperatively. Surgical complications were assessed from date of surgery through 24 months following study entry. Results. Early surgical complications were significantly more frequent in the bev group (25.4 vs. 18 .9%; trend test p = 0.008), but most were grade 1-2. Early noninfectious wound dehiscences were infrequent and not significantly different (5.4 vs. 3.1%; trend test p = 0.15). Long-term noninfectious wound complications were significantly higher for patients receiving bev (11.8 vs. 5.1%; trend test p = 0.0007), but the incidence of grade C3 wound dehiscence was low in both groups (\1%). Among 193 patients undergoing expander or implant reconstructions, 19 (19.6%) of 97 in the bev-receiving group versus 10 (10.4%) of 96 in the non-bev group had grade C3 complications (Pearson, p = 0.11). Conclusions. Overall, adding bev increased surgical complications, but most serious complications were not significantly increased. In particular, the need for surgical intervention in patients undergoing breast reconstruction with prosthetic implants was higher with bev but was not statistically significantly different. With precautions, bev can be used safely perioperatively in patients undergoing surgery for breast cancer.
Antiangiogenic compounds were predicted to have antitumor effects by Folkman and others more than four decades ago. 1 By inhibiting and even reversing new blood vessel formation in the tumor microenvironment, such agents potentially could deprive cancer cells of oxygen and nutrients and, by ''normalizing'' tumor vasculature, could possibly improve delivery of cytotoxic agents. 1, 2 The humanized monoclonal antibody to vascular endothelial growth factor A (VEGF), bevacizumab (bev), has clinical activity against a variety of cancer types, including glioblastoma and colorectal, breast, and lung cancer. [3] [4] [5] [6] However, inhibition of blood vessel formation via bev or other anti-angiogenic agents can impair wound healing. [7] [8] [9] [10] [11] [12] Based on the 20-day half-life of bev and the biology of wound healing, it has been recommended that elective surgery be delayed 4-8 weeks after the last dose of bev* and that bev should be started or resumed 2-4 weeks after surgery. [13] [14] [15] This concern has been raised for patients with metastatic colorectal cancer who are candidates for liver resection after a period of chemotherapy plus bev. However, with judicious timing of surgery, an increased risk of wound complications has not been consistently reported. [16] [17] [18] [19] Conversely, there have been observations of increased incidence of wound breakdown after craniotomies and port placements for patients who had received or subsequently were treated with bev. [20] [21] [22] However, none of these data have come from randomized, controlled trials. In two prospective trials of bev for metastatic breast cancer (AVADO and ATHENA), statistically significant increases in wound complications were not observed in patients receiving this agent and undergoing surgery. 23 However, not all patients in these trials had surgery, and many of the surgical procedures were neither major nor directed at the breast primary tumors.
Concerns have been raised for patients undergoing breast surgery after neoadjuvant chemotherapy (NCT), including bev, especially for women who undergo mastectomy with reconstruction. In one retrospective study, more implants placed for reconstruction were removed in the bev group than in the non-bev group, but there was no statistically significant difference in overall wound complications. 24 A later retrospective report, using matched controls who received NCT without bev, also found no difference in overall wound complication rates (32 vs. 31%), but indicated that 30% of women with implant reconstructions after bev had complications, and two with wound breakdown lost implants. 25 The National Surgical Adjuvant Breast and Bowel Project (NSABP) undertook a prospective randomized trial of NCT with or without bev for women with stage II-III operable breast cancer, accruing 1206 patients from 2007 to 2010. Patients randomly assigned to receive bev preoperatively also were to receive bev for 30 weeks postoperatively. The results, in terms of tumor response, early wound complication rates, and long-term outcomes, have been reported previously. 26, 27 However, with the concerns outlined above, we sought to examine the relative rates of both early and late surgical complications in more detail. This is the first study to evaluate the short-and long-term complication rates in a large, prospective trial in patients randomly assigned to NCT without bev versus those assigned to NCT plus bev, with bev administered both preoperatively and postoperatively.
METHODS
These trials were approved by local human investigations committees or institutional review boards in accordance with assurances filed with and approved by the Department of Health and Human Services. Written, informed consent was required for participation.
Trial Design
Our primary hypotheses were that addition of capecitabine, gemcitabine, and/or bev to NCT would increase pathologic complete response (pCR) rates in the breast for women with operable HER2-nonamplified breast cancer. Surgical complication was a prespecified secondary endpoint. Key eligibility requirements included palpable primary breast tumors, clinical stage T1c (if 2.0 cm), T2 or T3, and N0-N2a, M0; ECOG performance status of 0 or 1, and normal cardiac function. Patients were randomly assigned to receive docetaxel, capecitabine plus docetaxel, or gemcitabine plus docetaxel every 3 weeks for 4 cycles, followed by doxorubicin plus cyclophosphamide every 3 weeks for 4 cycles. Additionally, half were randomly assigned to receive or not to receive bev (15 mg/kg) on day 1 of each of the first 6 cycles of chemotherapy. To minimize risk of operative morbidity, bev was stopped after cycle 6 to allow at least a 9-week ''washout'' period before surgery. For patients who stopped treatment early for any * Current USPI labelling for bev states: ''Discontinue in patients with wound dehiscence. Discontinue at least 28 days prior to elective surgery. Do not initiate Avastin for at least 28 days after surgery and until the surgical wound is fully healed.'' reason, it was advised that surgery be delayed 4-6 weeks from the last dose of bev. The choice of breast-conserving surgery (BCS) versus mastectomy was at investigator discretion, as was the decision to perform immediate reconstruction. However, if tissue expanders were used, no expansion was allowed beyond 2 weeks before the first postoperative dose of bev, and no expansions or elective surgery was allowed throughout the course of bev therapy, which was intended to be 10 doses at 3-week intervals. Breast radiotherapy was required for patients undergoing BCS; the addition of regional-nodal irradiation or postmastectomy radiotherapy was at the treating physician's discretion.
Breast reconstruction and late surgical complications data were collected by submission of additional case report forms from each participating site. Data were collected on all surgical complications as well as on infections and noninfectious wound complications from surgery to 3-5 weeks following surgery, and from the previous time interval to 9, 12, and 24 months following entry. We initially used CTCAE, v3.0 to grade the severity of all complications but early in the trial switched to CTCAE, v4.0 (Table 1) . Early complications were defined as those occurring 3-5 weeks from the date of surgery, and those occurring later were defined as late complications.
Statistical Methods
Contingency table analyses were performed to estimate the proportion of surgical complications over time and to compare the surgical complications between the bev and non-bev groups in all eligible patients or those who had ever had breast reconstruction. Both the Pearson v 2 test with continuity correction and the Cochran-Armitage trend test were performed in the comparisons. 28 A test result was considered statistically significant if the corresponding p value was B0.05.
RESULTS

Early Complications
Among 1206 patients randomly assigned in the NSABP B-40 study, 1183 were eligible and 1157 (579 in the bev group, 578 in the non-bev group) underwent breast surgery. Among those 1157 patients, 1154 (577 in each group) had assessment of postoperative surgical complications. At 3-5 weeks after surgery, 1122 had assessment of surgical complications (560 in the bev group, 562 in the non-bev group). Overall highest grades of surgical complications are shown in Fig. 1a and the Supplementary Table. The rate of early complications was statistically significantly higher in the bev group (Pearson p = 0.22; trend test p = 0.008). However, rates of early noninfectious surgical complications were not statistically significantly different between groups (Fig. 1b) 
.3% for wound infections).
Longer-Term Complications After Surgery
Overall highest grades of surgical complications at all time points and at 9, 12, and 24 months after study entry are shown in Fig. 2a-d and the Supplementary Table. At all time points, the incidence of complications was statistically significantly higher for patients receiving bev, but most were mild (grades 1-2). The incidence of noninfectious wound dehiscence overall and at later time points is shown in Fig. 3a-d . The rate of these events was statistically significantly higher overall and at 9 and 12 months (trend test p = 0.0007, 0.007, and 0.0001). However, at all time points, the incidence of serious (grade C3) wound 
Specific Wound Complications in Patients Who Underwent Reconstruction
Among the 620 patients with mastectomies, data on breast reconstruction were submitted from 612 (bev: 300, non-bev: 312). Similar proportions underwent breast reconstruction: 124 (41%) of 300 in the bev group and 130 (42%) of 312 in the non-bev group (Fig. 4a) . There was no statistically significant difference in the types of breast reconstruction between the two arms (Pearson p = 0.50, 0.86, 1, and 0.14, respectively; Of the 620 patients who underwent mastectomy, 432 (69.7%) had postmastectomy radiotherapy, 178 did not, and no information on the use of radiotherapy was available from the other 10. Among those 432 who received radiotherapy, 47 (10.9%) had grade 3-4 complications: 29 (13.7%) among 211 bev patients and 18 (8.1%) among 221 non-bev patients (Pearson p = 0.09). Of those 178 who did not receive radiotherapy, 18 (10.1%) experienced grade 3-4 complications: 12 (13.8%) of 87 bev patients and 6 (6.6%) of 91 non-bev patients (Pearson p = 0.18). Results from logistic regression models suggested that, among patients with mastectomy, the incidence of serious (grade C3) surgical complications was higher in those randomized to bev (OR 2.02, 95% CI 1.19, 3.52; p = 0.01) and in those who underwent breast reconstruction (OR 1.80, 95% CI 1.06, 3.08; p = 0.03). The incidence of any surgical complication was higher in patients randomized to bev (OR 1.91, 95% CI 1.35, 2.71; p = 0.0003) but was related to neither breast reconstruction (p = 0.16) nor to radiotherapy (p = 0.41).
DISCUSSION
With the advent of therapeutic agents that inhibit angiogenesis, there has been concern that using such drugs in the perioperative period might increase the rates of surgical complications, particularly wound healing. This concern has been increased because of the more frequent use of systemic therapy before and immediately after surgery. Of particular concern has been the compromise of wounds that are being subjected to increased tension because of implantation and expansion of prosthetic tissue expanders used in breast reconstruction. For this reason, the NSABP B-40 protocol incorporated a number of safeguards regarding the use of these devices. Despite these precautions, there was a statistically significant increase in overall surgical complications in patients who were assigned to bev. Among those who underwent prosthetic reconstruction after mastectomy, 19.6% suffered grade C3 wound complications, requiring surgical intervention, compared to 10.4% for the non-bev group. However, this was not a statistically significant difference. Even though there was a statistically nonsignificant increase in dehiscences, the precautions built into this protocol should serve as useful guidelines for subsequent breast cancer patients receiving antiangiogenic therapy in the perioperative period.
The potential relevance of these findings to the care of future breast cancer patients is uncertain because of the conflicting results regarding the benefit of adding bev to chemotherapy for breast cancer. 6 Despite improvements in progression-free survival for patients with metastatic disease, improvements in overall survival (OS) did not materialize, and trials of bev added to adjuvant chemotherapy were negative. [29] [30] [31] [32] [33] [34] In the neoadjuvant setting, some trials showed improvements in pCR rates with added bev, particularly for triple-negative breast cancers, but this did not translate into long-term benefits in terms of disease-free survival or OS. [35] [36] [37] However, a recently reported randomized trial demonstrated an increase in pCR, as well as a trend toward improved event-free survival with the addition of bev to NCT for locally advanced and inflammatory triple-negative breast cancer. 38 In contrast, the B-40 trial demonstrated increased pCR rates with bev, preferentially in hormone-receptor positive breast cancer, and there also was an increase in OS for those who received bev. 26, 27 Nevertheless, because of the inconsistent results with this drug, the results of B-40 are not likely to change practice. However, B-40 was unique in that bev was given both before and after surgery. Future studies taking advantage of the tumor biopsies that were collected for research before treatment in this study may define a subset of patients who more clearly derive benefit from the addition of bev to NCT. If so, then this may result in the incorporation of bev in certain patients, and then the data presented will certainly be relevant. Even if bev does not become used in the therapy of breast cancer, the findings reported provide important insights relative to surgical complications that may be relevant for cancers such as those of the colon, lung, ovary, cervix, and kidney, and for glioblastoma multiforme, for all of which this drug is now commonly used.
CONCLUSIONS
This is the first report of a large, prospective randomized trial evaluating the short-and long-term complication rates from surgery in patients randomly assigned to receive or not to receive bevacizumab as neoadjuvant and adjuvant therapy. Despite the overall increase in surgical complications with the addition of bev, serious complications were, for the most part, not statistically significantly increased. In particular, the need for surgical intervention in patients undergoing breast reconstruction with prosthetic implants was higher but not statistically significantly different. With appropriate precautions, the risks of breast surgery, with or without reconstruction, should not bar the use of bev for patients with breast cancer.
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